Arisha Patel, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic Farah, Robert L. Redner, Annie Im, Kathleen A. Dorritie, Alison Sehgal, James Rossetti, Melissa Saul, Daniel Normolle, Konstantinos Lontos, Michael Boyiadzis
Oncology Research, Vol.28, No.7-8, pp. 811-814, 2020, DOI:10.3727/096504020X15965357399750
Abstract Leukemia relapse 5 years after achieving first complete remission (CR1) is uncommon in patients with acute
myeloid leukemia (AML). In this study, we evaluated the outcomes of AML patients with late relapse at our
institution and reviewed the literature for these patients. The study cohort consisted of nine AML patients with
late relapse. The median interval between CR1 and AML relapse was 6.1 years (range: 5.1–16.2 years). At
relapse, the karyotype was different from the initial AML diagnosis in 50% of patients. At the time of AML
relapse, seven patients received induction chemotherapy and two More >
Login
Register
